Generic Name and Formulations:
Ertapenem (as sodium) 1g; pwd for IV infusion after reconstitution and dilution; or for IM inj after reconstitution; sodium content 6mEq/g.
Merck & Co., Inc.
Indications for INVANZ:
Susceptible moderate to severe infections including complicated intraabdominal, complicated skin and skin structure, community-acquired pneumonia, complicated UTIs, acute pelvic infections. Prevention of surgical site infection following elective colorectal surgery in adults.
Adults and Children:
Do not mix or co-infuse with other meds or diluents containing dextrose. Give by IV infusion over 30 minutes for up to 14 days; or, give by IM inj for up to 7 days (for IM: see note). <3months: not recommended. 3months–12yrs: 15mg/kg twice daily (max 1g/day). ≥13yrs: 1g once daily; renal dysfunction (CrCl ≤30mL/min): 500mg once daily (give supplemental 150mg after session if dosed within 6 hours of hemodialysis). Intraabdominal: treat 5–14 days. Skin and skin structure: treat 7–14 days. Pneumonia, UTIs: treat 10–14 days (may switch to oral antibiotic after 3 days). Pelvic: treat 3–10 days. Adult prophylaxis in colorectal surgery: 1g single IV dose given 1 hour prior to surgical incision.
Penicillin, cephalosporin, or other β-lactam allergy. IM administration in patients with known hypersensitivity to amide-type local anesthetics.
CNS disorders (eg, brain lesions, seizure history). Renal dysfunction. Avoid extravasation. Monitor renal, hepatic, and hematopoetic function in prolonged use. Avoid blood vessel if administering by IM. Elderly. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid: not recommended. Antagonizes valproic acid or divalproex sodium: not recommended; consider other antibacterials.
Diarrhea (evaluate if occurs), nausea, vomiting, inj site reactions (thrombophlebitis/phlebitis), headache, CNS effects (dizziness, altered mental state, rarely: seizures), edema, dyspnea, fever.
For IM use, reconstitute with lidocaine 1% only; see full labeling.
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Presence of Iris Pigmented Lesions Indicates Melanoma Risk
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT
- Prognostic Significance of Epidermal Growth Factor Receptor Expression in Glioma Patients
- Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|